RIZMOIC

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug RIZMOIC contains one active pharmaceutical ingredient (API):

1	Naldemedine UNII V1N8F1RVVO - NALDEMEDINE TOSYLATE
	Naldemedine is an antagonist of opioid binding at the mu-, delta-, and kappa-opioid receptors. Naldemedine functions as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids without reversing the central nervous system (CNS)-mediated opioid effects.
	Read more about Naldemedine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RIZMOIC Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A06AH05		A Alimentary tract and metabolism → A06 Laxatives → A06A Laxatives → A06AH Peripheral opioid receptor antagonists
Discover more medicines within A06AH05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1789588, 1789599, 1789601, 1808568, 1808579, 1808580, 1808591
ES	Centro de información online de medicamentos de la AEMPS	1181291002
FR	Base de données publique des médicaments	66266368
GB	Medicines & Healthcare Products Regulatory Agency	377654
IT	Agenzia del Farmaco	047626015, 047626027, 047626039, 047626041, 047626054, 047626066
LT	Valstybinė vaistų kontrolės tarnyba	1087063, 1087064, 1087065, 1088429, 1088430, 1088431
PL	Rejestru Produktów Leczniczych	100417040